# Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene

> **NCT00386399** · PHASE2 · WITHDRAWN · sponsor: **Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins**

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Mitomycin-C

## Key facts

- **NCT ID:** NCT00386399
- **Lead sponsor:** Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2006-10
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** All consented subjects tested negative for the BRCA2 mutation, therefore, did not meet criteria to start the study, resulting in withdrawal by PI
- **Last updated:** 2018-07-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00386399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00386399, "Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00386399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*